Diplomat Pharmacy, Inc. (DPLO) Stock Is At All-Time on Mar, 15

Diplomat Pharmacy, Inc. (NYSE:DPLO) Corporate Logo

Big Money Sentiment increased to 1.06 in Q4 2018. It has change of 0.05, from 2018Q3’s 1.01. The ratio is positive due to Diplomat Pharmacy, Inc. positioning: 26 sold and 42 reduced. 19 funds took holdings and 53 increased holdings. Investors holded 61.77 million in 2018Q3 but now own 63.85 million shares or 3.37% more.
Pnc Fin Service Inc holds 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO) or 1,908 shs. Indiana-based Old National Financial Bank In has invested 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Sector Pension Invest Board, a Quebec – Canada-based fund reported 49,600 shs. Massmutual Trust Fsb Adv stated it has 95 shs. Moreover, Texas Permanent School Fund has 0.01% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 37,039 shs. 152 are held by Glenmede Na. Engineers Gate Manager Limited Partnership stated it has 75,952 shs. Telemus Lc invested in 0.01% or 12,275 shs. Ftb Advisors, a Tennessee-based fund reported 755 shs. Pennsylvania-based Federated Pa has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Bnp Paribas Arbitrage holds 0% of its capital in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 2,396 shs. Northern Tru owns 1.29M shs for 0% of their capital. Comml Bank Of Mellon Corporation accumulated 0.01% or 1.68M shs. Cubist Systematic Strategies Limited reported 11,468 shs. Swiss Commercial Bank holds 0% or 92,100 shs in its capital.

Diplomat Pharmacy, Inc. (NYSE:DPLO) touched all time low on Mar, 15 with $5.37 price target or 8.00 % below the last $5.84 share price. Barchart.com reported this chart pattern. The company has $434.64 million MC. At $5.37 stock price target, the company valuation changes by $34.77 million less.

DPLO is reaching $5.84 during the last trading session, after decreased 9.03%.Diplomat Pharmacy, Inc. has 1.36M shares volume, 5.62% up from normal. DPLO is downtrending and has moved 69.53% since March 15, 2018. DPLO underperformed by 73.90% the S&P500.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Ratings Coverage

In total 5 analysts cover Diplomat Pharmacy (NYSE:DPLO). “Buy” rating has 1, “Sell” are 0, while 4 are “Hold”. 20% are bullish. 11 are the (NYSE:DPLO)’s analyst reports since November 7, 2018 according to StockzIntelligence Inc. On Friday, February 22 the firm has “Hold” rating given by Mizuho. On Monday, February 25 the rating was maintained by Barclays Capital with “Buy”. On Thursday, November 8 the stock has “Market Perform” rating by Wells Fargo. In Monday, December 3 report Morgan Stanley maintained it with “Equal-Weight” rating and $18 target. In Friday, December 7 report Robert W. Baird upgraded it to “Neutral” rating and $15 target. On Wednesday, November 7 Robert W. Baird downgraded Diplomat Pharmacy, Inc. (NYSE:DPLO) to “Underperform” rating.

For more Diplomat Pharmacy, Inc. (NYSE:DPLO) news brought out briefly go to: Globenewswire.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Businesswire.com. The titles are as follows: “SECURITIES CLASS ACTION REMINDERS for TAP, SYNH, WRCDF and DPLO Investors: Hagens Berman Reminds Investors of Class Actions and Lead Plaintiff Deadlines – GlobeNewswire” brought out on March 15, 2019, “KHC, Z, ROKU, IQ and TTD among notable midday movers – Seeking Alpha” on February 22, 2019, “Daily Biotech Pulse: KaryoPharm’s Selinexor Review Delayed, FDA Accepts Adamas Opioid Overdose Drug NDA – Benzinga” with a publish date: March 15, 2019, “CLASS ACTION UPDATE for MU, AVEO, DPLO and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” and the last “LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 Investing In Diplomat Pharmacy, Inc. To Contact The Firm – Business Wire” with publication date: March 11, 2019.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States.The firm is worth $434.64 million. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers.188.39 is the P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.